Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: A randomised, controlled, double-blind, phase 2 trial

The Lancet Oncology

Volumn 14, Issue 3, 2013, Pages 228-235

  Robertson, John FR ^a   Ferrero, Jean Marc ^b   Bourgeois, Hugues ^c   Kennecke, Hagen ^d   de Boer, Richard H ^e   Jacot, William ^f   McGreivy, Jesse ^g   Suzuki, Samuel ^g   Zhu, Min ^g   McCaffery, Ian ^g   Loh, Elwyn ^g   Gansert, Jennifer L ^g   Kaufman, Peter A ^h  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c Clinique Victor Hugo   (France)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f CENTRE VAL D AURELLE   (France)

^g AMGEN INC   (United States)

^h DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GANITUMAB; PLACEBO; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; ANDROSTADIENES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECEPTOR, ERBB-2;

EID: 84875257995     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70026-3     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011, 103:250-263.
3. Hurvitz SA, Pietras RJ Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008, 113:2385-2397.
4. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92:2247-2258.
5. Mouridsen HT Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007, 105(suppl 1):19-29.
6. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
7. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670.
8. Jones HE, Gee JM, Hutcheson IR, Nicholson RI Insulin-like growth factor-I receptor signaling and resistance in breast cancer. Expert Rev Endocrin Metab 2006, 1:33-46.
9. Pollak M Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
10. Martin LA, Pancholi S, Chan CM, et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005, 12:1017-1036.
11. Parisot JP, Leeding KS, Hu XF, DeLuise M, Zalcberg JR, Bach LA Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res Treat 1999, 55:231-242.
12. Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE, Westley BR Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 1993, 29A:2256-2264.
13. Fox EM, Miller TW, Balko JM, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 2011, 71:6773-6784.
14. Santen RJ, Song RX, McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002, 80:239-256.
15. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005, 146:4609-4618.
16. Sachdev D, Yee D Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007, 6:1-12.
17. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009, 8:1095-1105.
18. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009, 27:5800-5807.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
20. Branson M, Whitehead J Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 2002, 21:2449-2463.
21. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
22. Traina TA, Poggesi I, Robson M, et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 2008, 111:377-388.
23. AstraZeneca. Faslodex® (fulvestrant). USA prescribing information. 2010.
24. Santarpia L, Qi Y, Stemke-Hale K, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012, 134:333-343.
25. Liu P, Cheng H, Roberts TM, Zhao JJ Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
26. Nicholson RI, Hutcheson IR, Knowlden JM, et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10:346S-354S.
27. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11:793-814.
28. Knowlden JM, Hutcheson IR, Gee JM, Barrow D, Wakeling AE, Nicholson RI Gefitinib (IRESSA) promotes IGF-1R signalling in tamoxifen-resistant MCF-7 breast cancer cells: role of IRS-1. Breast Cancer Res Treat 2004, 88(suppl 1). abstr 1111.
29. Drury SC, Detre S, Leary A, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 2011, 18:565-577.
30. Fagan DH, Uselman RR, Sachdev D, Yee D Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 2012, 72:3372-3380.
31. Reidy DL, Vakiani E, Fakih MG, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010, 28:4240-4246.
32. Beltran PJ, Chung YA, Moody G, et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011, 337:644-654.
33. Gualberto A, Pollak M Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28:3009-3021.